Samuel C. Blackman Sells 10,000 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 10,000 shares of the stock in a transaction on Monday, March 25th. The stock was sold at an average price of $16.01, for a total value of $160,100.00. Following the sale, the insider now directly owns 1,184,662 shares of the company’s stock, valued at $18,966,438.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Day One Biopharmaceuticals Stock Up 1.7 %

Shares of DAWN stock opened at $15.79 on Thursday. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $9.67 and a fifty-two week high of $17.85. The stock has a market cap of $1.38 billion, a P/E ratio of -6.63 and a beta of -1.48. The business has a fifty day simple moving average of $15.11 and a 200-day simple moving average of $13.52.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). On average, sell-side analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on DAWN shares. The Goldman Sachs Group cut their price objective on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Piper Sandler reiterated an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday. Finally, Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $40.60.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its position in shares of Day One Biopharmaceuticals by 38.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 447,138 shares of the company’s stock valued at $5,486,000 after buying an additional 125,050 shares in the last quarter. Bank of New York Mellon Corp increased its position in Day One Biopharmaceuticals by 22.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock worth $2,703,000 after purchasing an additional 40,387 shares in the last quarter. Deutsche Bank AG increased its position in Day One Biopharmaceuticals by 5.5% during the 3rd quarter. Deutsche Bank AG now owns 177,137 shares of the company’s stock worth $2,173,000 after purchasing an additional 9,219 shares in the last quarter. Citigroup Inc. increased its position in Day One Biopharmaceuticals by 4.4% during the 3rd quarter. Citigroup Inc. now owns 100,665 shares of the company’s stock worth $1,235,000 after purchasing an additional 4,234 shares in the last quarter. Finally, TimesSquare Capital Management LLC increased its position in Day One Biopharmaceuticals by 41.8% during the 3rd quarter. TimesSquare Capital Management LLC now owns 1,142,610 shares of the company’s stock worth $14,020,000 after purchasing an additional 336,910 shares in the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.